display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - L1 - BRAF mutant
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC IMspire-150 ...

Study type: